Takeda picks first woman as CEO of centuries-old drugmaker
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
FiercePharma17h
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
ジャパンタイムズ1d
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...
Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed
Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.
Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
BioSpace1d
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...